L'intérêt à découvert pour Axos Financial donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Axos Financial. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Axos Financial (NYSE:AX) Stock, Rapport sur les intérêts à découvert

Axos Financial

Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment . The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.

Axos Financial Inc

HSBC BANK 13/11/24 WNT

AXIOS SUSTANBLE GRWTH A by AXIOS Sustainable Growth Acquisition Corporation

AXIOS Sustainable Growth Acquisition Corp

AXA SA

AXA ORD

Abraxas Petroleum Corp

AXIS BANK GDR

AXIS BANK 144A GDR

AXIS BANK LTD S/GDR 144A by Axis Bank Ltd.

Axis Bank Ltd

AXIOS MOBILE ASSETS ORD by Axios Mobile Assets Corp.

Axios Mobile Assets Corp

EYES ON THE GO INC by Eyes on the Go, Inc.

Eyes on the Go Inc

ALLIXON INTL CORP by Allixon International Corp.

Allixon International Corp

AZUCAR MINERALS LTD by Azucar Minerals Ltd.

Azucar Minerals Ltd

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics Inc

ISH ACTAXEE ETF

AXEL

Axfood AB

AXIS ENERGY CORP by Axis Energy Corporation

Axis Energy Corp

ACCENT GROUP LTD by ACCENT GROUP LTD.

Axogen Inc

ALEXIUM INTL GRP LTD ORD by Alexium International Group Ltd.

Alexium International Group Ltd

AXIL Brands Inc

AXIM BIOTECHNOLOGIES INC by Axim Biotechnologies, Inc.

AXIM Biotechnologies Inc

AXIS Token

American Axle & Manufacturing Holdings, Inc. Common Stock

American Axle & Mfg Holdings Inc

Axelar - United States Dollar

Axiologix Inc

AXMIN Inc

AXM PHARMA INC by AXM Pharma, Inc.

ALLIANCE NICKEL LTD by ALLIANCE NICKEL LTD

Alliance Nickel Ltd

AXION VENTURES INC by Axion Ventures Inc.

Axion Ventures Inc

Axonics Inc

Axon Enterprise Inc

American Express Co

AXPR

AXIS PETROLEUM CO CAP by Axis Petroleum Co.

AXION POWER INTL INC by Axion Power International, Inc.

Axion Power International Inc

AMERICAN EXPRESS ORD

Amrep Corp

AMARC RESOURCE LTD by Amarc Resources Ltd.

Amarc Resources Ltd

Amexdrug Corp

Axis Capital Holdings Limited Common Stock

Axis Capital Holdings Ltd

Axie Infinity - United States Dollar

Axsome Therapeutics Inc

Axis Capital Holdings Limited Depositary Shares, each representing 1/100th interest in a share of a 5.50% Series E Preferred Shares

Axalta Coating Systems Ltd. Common Shares

Axalta Coating Systems Ltd

AXALTA COATING SYSTEMS ORD

AXIS TECHS GROUP INC by Axis Technologies Group, Inc.

Axis Technologies Group Inc

AXT Inc

AXTEL SAB DE CV B by Axtel S. A.. B. De CV

Axtel SAB de CV

CDN MAVERICK CAP CORP by CDN MAVERICK CAP CORP.

CDN Maverick Capital Corp

Exxe Group Inc

ALDERON IRON ORE CORP by Alderon Iron Ore Corp.

Alderon Iron Ore Corp

Axiata Group Bhd

<a href="https://www.reuters.com/world/us/kamala-harris-highlight-economic-policies-black-men-next-week-sources-say-2024-10-11/" title="https://www.reuters.com/world/us/kamala-harris-highlight-economic-policies-black-men-next-week-sources-say-2024-10-11/">https://www.reuters.com/world/us/kamala-harris-highlight-economic-policies-black-men-next-week-sources-say-2024-10-11/</a>

News

Politics

General

Kamala Harris To Highlight Economic Policies Benefiting Black Men Next Week As Campaign Sees Weakness In Key Voting Bloc; Harris Announcement On Policies For Black Men Timed For Tuesday Interview With Radio Host Charlamagne Tha God In Detroit, Michigan; Will Discuss Access To Capital For Black Entrepreneurs, Small Business Growth, Housing; Will Not Address Racial Justice Issues

JMP Securities analyst Silvan Tuerkcan reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Market Outperform and maintains $29 price target.

Price Target

Reiteration

Analyst Ratings

EXEL

JMP Securities Reiterates Market Outperform on Exelixis, Maintains $29 Price Target

Chardan Capital analyst Keay Nakae maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $300 price target.

ALNY

Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Maintains $300 Price Target

JMP Securities analyst Aaron Kimson maintains Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) with a Market Outperform and raises the price target from $179 to $200.

GWRE

JMP Securities Maintains Market Outperform on Guidewire Software, Raises Price Target to $200

Telsey Advisory Group analyst Dana Telsey maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Market Perform and maintains $26 price target.

Telsey Advisory Group Maintains Market Perform on Gap, Maintains $26 Price Target

A sudden single-day spike by Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) has prompted traders to predict an upcoming bull run for <a href="https://www.benzinga.com/topic/meme-coins">the meme coin leaders.</a>
What Happened: With Dogecoin prices reflecting a relatively flat performance over the past week, an analyst who goes by &#8220;Kevin&#8221; on X, outlined his thoughts on the trajectory of Dogecoin. He stated that the meme coin is still trying to establish a successful bullish retest of its macro falling wedge, following its typical bull market correction of 60%.
After Friday&#8217;s price jump of 5%, Kevin further <a href="https://x.com/Kev_Capital_TA/status/1844725417569145294">predicted</a> that if this retest is successful, it could be the last opportunity to purchase Dogecoin at its current prices.
As Shiba Inu prices rally higher, crypto trader Javon Marks asked the crypto community, "Are you prepared for $0.000081?" He added that Shib has broken out of a recent falling wedge pattern and a much larger (unpictured) resisting trend.
He <a href="https://x.com/JavonTM1/status/1844779511864266898">predicts</a> a more than 342% rally from here, as this falling wedge will only help to &#8220;spark the process.&#8221;
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41207040/dogecoin-killer-shiba-inu-up-39-over-the-past-30-days-but-that-will-accelerate-says-bullis">&#8216;Dogecoin Killer&#8217; Shiba Inu Up 39% Over The Past 30 Days But That &#8216;Will Accelerate,&#8217; Says Bullish Trader</a>
Why It Matters: Kevin's analysis suggests that Dogecoin is currently in a critical phase of its market cycle. If his prediction holds true, this could mean a significant uptick in the value of Dogecoin.
Meanwhile, Marks&#8217; prediction reflects a highly bullish run for Shiba Inu, which has already accumulated 34% over the past month. Shibburn data shows an increase of 83.4% in its burn rate over the past 24 hours as 4.6 million SHIB coins are thrown out of the ecosystem.
IntoTheBlock data shows that Doge and Shiba&#8217;s large transaction volume decreased by 23.8% and 35.5%, respectively. Daily active addresses for Dogecoin and Shiba Inu surged by 176.7% and 13.7%.
Dogecoin transactions greater than $100,000 increased from 227 to 251 in a single day, while Shiba Inu saw a marginal increase from 110 to 118. DOGE exchanges&#8217; net flows are down by 199%.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41209298/dogecoin-gearing-up-for-next-big-rally-this-is-the-price-traders-are-targeting">Dogecoin &#8216;Gearing Up For Next Big Rally&#8217;: This Is The Price Traders Are Targeting</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Trading Ideas

$DOGE

$SHIB

What's Going On With Dogecoin, Shiba Inu Today?

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

Wedbush analyst Jay McCanless maintains Cavco Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVCO#NASDAQ">CVCO</a>) with a Outperform and raises the price target from $425 to $455.

CVCO

Wedbush Maintains Outperform on Cavco Indus, Raises Price Target to $455

Telsey Advisory Group analyst Joe Feldman maintains Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with a Market Perform and maintains $27.25 price target.

Telsey Advisory Group Maintains Market Perform on Albertsons Companies, Maintains $27.25 Price Target

ShiftPixy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PIXY#NYSE">PIXY</a>) short percent of float has risen 64.94% since its last report. The company recently reported that it has 157 thousand shares sold short, which is 5.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.12 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>ShiftPixy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728670522_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ShiftPixy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing ShiftPixy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ShiftPixy's peer group average for short interest as a percentage of float is 1.42%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

PIXY

How Is The Market Feeling About ShiftPixy?

New Fortress Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NYSE">NFE</a>) short percent of float has fallen 39.61% since its last report. The company recently reported that it has 24.76 million shares sold short, which is 19.85% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.83 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>New Fortress Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728670517_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for New Fortress Energy has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing New Fortress Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, New Fortress Energy's peer group average for short interest as a percentage of float is 4.33%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(NFE) - Analyzing New Fortress Energy's Short Interest

UiPath's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) short percent of float has fallen 25.0% since its last report. The company recently reported that it has 23.76 million shares sold short, which is 5.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>UiPath Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728670512_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for UiPath has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing UiPath's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, UiPath's peer group average for short interest as a percentage of float is 4.90%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

PATH

How Is The Market Feeling About UiPath?

EF Hutton analyst Jason Kolbert maintains Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) with a Buy and maintains $23 price target.

MRNS

EF Hutton Maintains Buy on Marinus Pharma, Maintains $23 Price Target

Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) shares are trading higher on Friday. Warren Buffet&#8217;s Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) sold more of its shares in the bank, bringing its <a href="https://www.benzinga.com/markets/equities/24/10/41294370/warren-buffett-continues-trimming-bank-of-america-position-no-longer-needs-to-report-sales">stake below 10%</a>.
The Details: According to a Securities and Exchange Commission (SEC) filing, Berkshire Hathaway sold a total of 9.5 million Bank of America shares at an average price of $40.04 per share.
Berkshire made this move via three separate sales throughout the week with 3.9 million shares sold on Tuesday, 4 million shares sold on Wednesday and 1.6 million shares sold on Thursday.
Berkshire now holds a 9.98% stake in the bank which is equivalent to 775 million shares. Now that Berkshire Hathaway&#8217;s stake in Bank of America is below 10%, the company is no longer required to promptly report these transactions to the SEC.
Berkshire has been slowly selling off its Bank of America shares for quite some time now. Back in August, the company sold shares worth than <a href="https://www.benzinga.com/news/24/08/40471316/whats-going-on-with-bank-of-america-shares-tuesday">$550 million</a>. Berkshire also sold Bank of America Shares in September and July.
Bank of America is not the only bank to experience a selloff of its shares by Berkshire. Buffet&#8217;s Berkshire Hathaway has been unloading shares in companies across the banking industry for years. In 2022, Berkshire sold its remaining Wells Fargo shares. Furthermore, throughout 2020, Berkshire dumped its stake in JPMorgan Chase.
This could indicate that Buffet sees more value in stocks outside the banking industry. According to <a href="https://www.cnn.com/2021/02/16/investing/berkshire-hathaway-warren-buffett-stocks/index.html">CNN</a>, Berkshire bought stake in Verizon and Chevron after it sold its shares in JPMorgan Chase.
How To Buy Bank of America Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)'s case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/markets/equities/24/10/41289653/tesla-stock-poised-to-pullback-to-1-month-low-whats-going-on">Tesla Stock Poised To Pullback To 1-Month Low: What&#8217;s Going On?</a>
BAC Price Action: At the time of writing, Bank of America stock is trading 4.94% higher at $41.95  per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>
Image: Image via Shutterstock

Movers

What's Going On With Bank Of America Stock Friday?

Wedbush analyst Seth Basham initiates coverage on Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) with a Neutral rating and announces Price Target of $11.

Initiation

ARHS

Wedbush Initiates Coverage On Arhaus with Neutral Rating, Announces Price Target of $11

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) have dominated the obesity drug market with their leading therapies, Wegovy and Zepbound, but the next generation of treatments could shift this dynamic.
These new drugs, expected to hit the market by 2029, aim to surpass current efficacy levels while offering more convenient dosing options, such as oral and monthly injections. This shift, driven by innovation and competition, could change the market landscape despite Novo and Lilly&#8217;s current hold on the sector.
According to a <a target="_blank" href="https://assets.contentstack.io/v3/assets/blt4eb669caa7dc65b2/blt79266ca5d3a390c1/Obesity_Drug_Market_Report.pdf" rel="noreferrer noopener">report</a> by Morningstar, the global GLP-1 market is poised to reach $200 billion by 2031, with obesity treatment expected to account for 68% of sales.
While Novo Nordisk and Eli Lilly are projected to retain two-thirds of this market, driven by first-mover advantage and robust pipelines, new competitors could claim significant market share.
Public and private biopharma firms are increasingly focusing on cardiometabolic drug development, with 16 new obesity drugs potentially launching by 2029 the report added.
This pipeline includes candidates from major players such as <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40422774/roche-misses-out-on-weight-loss-blockbuster-drug-now-playing-catch-up-in-booming-market" rel="noreferrer noopener">Roche Holdings AG</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and private companies like Boehringer Ingelheim.
Roche released topline results from the ongoing multi-part Phase 1 trial for CT-996, showing data better compared <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39817857/obesity-drugs-focused-stocks-tumble-on-wednesday-whats-going-on-with-eli-lilly-novo-nordisk-vikin" rel="noreferrer noopener">to existing competitors</a>. Despite Novo Nordisk and Eli Lilly&#8217;s strong market positions, some analysts view their stocks as overvalued.
Achieving the market penetration needed to justify their current valuations would require near-unprecedented success, including capturing 75% of the U.S. obesity market and 95% of the global market by 2031.
Additionally, maintaining stable pricing seems unlikely, with increased competition and innovation expected to put downward pressure on drug prices.
Supply chain issues pose further challenges. Both companies face difficulties in manufacturing peptide-based drugs at scale, such as Wegovy and Zepbound.
While oral peptide drugs like high-dose Novo Nordisk&#8217;s Rybelsus and Viking Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37937068/viking-therapeutics-investigational-oral-obesity-drug-shows-reduced-weight-in-small-study" rel="noreferrer noopener">VK2735 offer alternatives</a>, they may be even harder to supply due to the higher doses required for efficacy.
Small molecule drugs, like Lilly&#8217;s orforglipron and Pfizer&#8217;s<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39753273/with-oral-anti-obesity-candidate-development-pfizer-seeks-relevant-and-competitive-" rel="noreferrer noopener"> danuglipron</a>, offer the best potential for scalable production, promising more streamlined manufacturing processes.
New entrants to the obesity drug market are pushing the envelope, with drug candidates from companies like Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Altimmune Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), and Zealand Pharma (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZLDPF#OTC">ZLDPF</a>) on the horizon.
In a phase 1 study, Amgen&#8217;s AMG 133 showed an acceptable safety and tolerability profile and pronounced <a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36934096/weight-loss-drugs-new-entrant-amgen-to-compete-with-novo-nordisk-eli-lilly-as-investigational-wei" rel="noreferrer noopener">dose-dependent weight loss</a>.&nbsp;
Altimmune said the body composition study of pemvidutide showed preservation of lean mass, with 25.5% of weight loss derived from lean mass and 74.5% <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37958653/why-is-obesity-drug-developer-altimmune-stock-trading-lower-on-wednesday" rel="noreferrer noopener">from adipose tissue</a>.
These next-generation drugs could challenge the dominance of Novo and Lilly, especially if they offer better efficacy or fewer side effects.
However, Wegovy and Zepbound&#8217;s entrenched positions and ongoing innovation may keep Novo and Lilly at the forefront for the foreseeable future.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41295498/gsk-settles-majority-of-zantac-lawsuits-but-pipeline-doubts-remain" target="_blank" rel="noreferrer noopener">GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Analyst Color

Biotech

Large Cap

Health Care

AMGN

RHHBY

VKTX

ZLDPF

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names

CleanSpark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) shares are moving higher on Friday amid a rise in the price of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
The Details: Bitcoin is currently trading 3.4% higher at about $62,400 per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>. Other crypto-linked stocks that are moving higher amid the rise in the price of Bitcoin include Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>).
What Else: Earlier this week, CleanSpark announced that it achieved 30 EH/s in operational hashrate. The company plans to achieve 37 EH/s by the end of the year and 50 EH/s in 2025.
CEO of CleanSpark Zach Bradford said, &#8220;We have added more operational hashrate than any other miner in 2024.&#8221;
In addition, the company announced that it promoted Brian Carson to Chief Accounting Officer from Director of Financial Reporting.
How To Buy CleanSpark Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
CLSKFor example, in Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>)'s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/top-stories/24/10/41279865/elon-musk-may-unveil-teslas-robotaxi-but-consumers-respond-with-ehhh-new-study-reveals-skepticism-ne">Elon Musk May Unveil Tesla&#8217;s Robotaxi, But Consumers Respond With &#8216;Ehhh,&#8217; New Study Reveals Skepticism, Need For Trust-Building</a>
CLSK Price Action: At the time of writing, CleanSpark shares are trading 10.3% higher at $9.55, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Image via Shutterstock

$BTC

CLSK

COIN

RIOT

What's Going On With CleanSpark Shares Friday

Stephens &amp; Co. analyst Mike Scialla maintains Excelerate Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EE#NYSE">EE</a>) with a Overweight and raises the price target from $21 to $28.

Stephens & Co. Maintains Overweight on Excelerate Energy, Raises Price Target to $28

RBC Capital analyst Kenneth Lee maintains Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) with a Outperform and raises the price target from $500 to $535.

RBC Capital Maintains Outperform on Ameriprise Finl, Raises Price Target to $535

Barrington Research analyst Kevin Steinke maintains Crawford (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) with a Outperform and maintains $12 price target.

CRD/A

Barrington Research Maintains Outperform on Crawford, Maintains $12 Price Target

Companies in the Financial sector have received a lot of coverage today as analysts weigh in on Axos Financial (AX – Research Report) and NMI Holdi...

Analysts Offer Insights on Financial Companies: Axos Financial (AX) and NMI Holdings (NMIH)

D.A. Davidson analyst Gary Tenner maintained a Buy rating on Axos Financial (AX – Research Report) today and set a price target of $90.00. The comp...

D.A. Davidson Sticks to Its Buy Rating for Axos Financial (AX)

Axos Financial (AX) has issued an announcement. Axos Financial, Inc. is set to begin sharing a presentation with investors starting August 12, 2024...

Axos Financial Initiates Investor Presentation Series

Axos Financial: When Quality Deserves A Premium

NYCB, Qifu rise the most among financial stocks: weekly roundup

Stocks with three weeks of deteriorating technicals by Piper Sandler

Axos Bank: Taking An Axe To The Loan Book

Axos Financial ( ($AX) ) has issued an update. Axos Financial, Inc. has named Ann Gill as their new Senior Vice President and Chief Accounting Offi...

Axos Financial Appoints Ann Gill as New SVP and CAO

Axos Financial (AX) has received a new Buy rating, initiated by Needham analyst, Kyle Peterson. Kyle Peterson has given his Buy rating due to a com...

Comments

Axos Financial

Intérêt court

Axos Financial (NYSE:AX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL